Insulet Corp.

  • Market Cap: Mid Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US45784P1012
USD
315.92
6.92 (2.24%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Insulet Corp. stock-summary
stock-summary
Insulet Corp.
Pharmaceuticals & Biotechnology
Insulet Corporation is engaged in the development, manufacturing and sale of the OmniPod Insulin Management System (the OmniPod System), an insulin delivery system for people with insulin-dependent diabetes. The Omnipod System features a self-adhesive disposable tubeless Omnipod device, which is worn on the body for approximately three days at a time and its wireless companion, the handheld Personal Diabetes Manager (PDM). The Omnipod System features two discreet devices that eliminate the need for a bulky pump, tubing and separate blood glucose meter, provides for virtually pain-free automated cannula insertion, communicates wirelessly and integrates a blood glucose meter. The Omnipod System is a discreet two part design, the Omnipod device (Pod) and the PDM that eliminates the need for the external tubing required with conventional pumps. The Pod is a self-adhesive device that the patient fills with insulin and wears directly on the body.
Company Coordinates stock-summary
Company Details
100 Nagog Park , ACTON MA : 01720-3440
stock-summary
Tel: 1 978 60070001 978 6007717
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 151 Schemes (62.59%)

Foreign Institutions

Held by 369 Foreign Institutions (25.03%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. timothy Scannell
Independent Chairman of the Board
Ms. Shacey Petrovic
President, Chief Executive Officer, Director
Dr. Wayne Frederick
Director
Ms. Sally Crawford
Independent Director
Dr. John Fallon
Independent Director
Dr. James Hollingshead
Independent Director
Dr. Jessica Hopfield
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
649 Million
(Quarterly Results - Jun 2025)
Net Profit:
22 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 24,606 Million (Mid Cap)

stock-summary
P/E

51.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.20

stock-summary
Return on Equity

22.99%

stock-summary
Price to Book

16.82